Etanercept use for psoriasis in Taiwan: A case series study

International Journal of Dermatology

Volumn 52, Issue 6, 2013, Pages 673-680

  Chiu, Hsien Yi ^a   Wang, Ting Shun ^a   Cho, Yung Tsu ^a   Tsai, Tsen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETANERCEPT; ETRETIN; ISONIAZID; METHOTREXATE;

ADULT; AGED; ARTICLE; BODY MASS; CASE STUDY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; REIMBURSEMENT; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TAIWAN; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS CONTROL; ULTRAVIOLET B RADIATION;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878138983     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05273.x     Document Type: Article

References (44)

1. Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-675.
2. Chou CT, Tsai CY, Liang TH, et al. Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis. Mod Rheumatol 2010; 20: 580-587.
3. Brandt J, Listing J, Haibel H, et al. Longterm efficacy and safety of etanercept after re-administration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005; 44: 342-348.
4. Lan JL, Chou SJ, Chen DY, et al. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. J Formos Med Assoc 2004; 103: 618-623.
5. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004; 363: 675-681.
6. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15: 16-17.
7. Bowerman RJ. Tuberculin skin testing in BCG-vaccinated populations of adults and children at high risk for tuberculosis in Taiwan. Int J Tuberc Lung Dis 2004; 8: 1228-1233.
8. Chen DS, Sung JL. Hepatitis B virus infection and chronic liver disease in Taiwan. Acta Hepatogastroenterol (Stuttg) 1978; 25: 423-430.
9. Chen DY, Shen GH, Hsieh TY, et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59: 800-806.
10. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double-blind multicenter trial. BMJ 2010; 340: 147.
11. Zachariae C, Mork NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008; 88: 495-501.
12. Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat 2006; 17: 343-352.
13. Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol 2008; 159: 460-463.
14. Foley PA, Quirk C, Sullivan JR, et al. Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. J Eur Acad Dermatol Venereol 2010; 24: 1135-1143.
15. Heffernan MP. Combining traditional systemic and biologic therapies for psoriasis. Semin Cutan Med Surg 2010; 29: 67-69.
16. de Groot M, Appelman M, Spuls PI, et al. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808-814.
17. Jimenez-Puya R, Gomez-Garcia F, Amorrich-Campos V, Moreno-Gimenez JC. Etanercept: efficacy and safety. J Eur Acad Dermatol Venereol 2009; 23: 402-405.
18. Papp KA, Tyring S, Lahfa M, et al. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
19. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632; discussion: 1632.
20. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
21. Na JI, Kim JH, Park KC, Youn SW. Low-dose etanercept therapy in moderate to severe psoriasis in Korean. J Dermatol 2008; 35: 484-490.
22. Tsai TF, Liu MT, Liao YH, Licu D. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate to severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study. J Eur Acad Dermatol Venereol 2008; 22: 345-352.
23. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073-3080.
24. Huang PH, Liao YH, Wei CC, et al. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate to severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicenter pilot study. J Eur Acad Dermatol Venereol 2008; 22: 923-930.
25. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled Phase III trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-727.
26. Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
27. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled Phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
28. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
29. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate to severe psoriasis: a Phase III, multicenter, double-blind trial. Lancet 2005; 366: 1367-1374.
30. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842-1847.
31. Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-49.
32. Stuart PE, Nair RP, Hiremagalore R, et al. Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics shows locus heterogeneity at PSORS1. Tissue Antigens 2010; 76: 387-397.
33. Chang YT, Tsai SF, Lee DD, et al. A study of candidate genes for psoriasis near HLA-C in Chinese patients with psoriasis. Br J Dermatol 2003; 148: 418-423.
34. Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol 2007; 156: 1010-1014.
35. Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a UK tertiary referral centre. Br J Dermatol 2009; 160: 162-169.
36. Antoniou C, Dessinioti C, Stratigos A, et al. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience. J Eur Acad Dermatol Venereol 2009; 23: 979-982.
37. Martin B, Sanchez-Carazo JL, Perez-Ferriols A, et al. [Clinical experience with etanercept in the treatment of psoriasis.]Actas Dermosifiliogr 2008; 99: 540-545.
38. Krueger GG, Elewski B, Papp K, et al. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol 2006; 54(Suppl.): 112-119.
39. Tyring S, Gordon KB, Poulin Y, et al. Longterm safety and efficacy of 50mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
40. Lee EJ, Shin MK, Kim NI. A clinical trial of combination therapy with etanercept and low-dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol 2010; 22: 138-142.
41. Petitpain N, Gambier N, Wahl D, et al. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 2009; 19: 355-364.
42. Ferraccioli G, Gremese E. Thrombogenicity of TNF-alpha in rheumatoid arthritis defined through biological probes: TNF-alpha blockers. Autoimmun Rev 2004; 3: 261-266.
43. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 2010; 163: 586-592.
44. Tobin AM, Veale DJ, Fitzgerald O, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010; 37: 1386-1394.